A detailed history of Federated Hermes, Inc. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,329 shares of ALXO stock, worth $4,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,329
Previous 201,362 98.84%
Holding current value
$4,355
Previous $2.25 Million 99.38%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$5.84 - $17.56 $1.16 Million - $3.5 Million
-199,033 Reduced 98.84%
2,329 $14,000
Q1 2024

May 14, 2024

BUY
$10.95 - $16.79 $52,844 - $81,028
4,826 Added 2.46%
201,362 $2.25 Million
Q4 2023

Jan 31, 2024

SELL
$4.81 - $15.38 $263,703 - $843,193
-54,824 Reduced 21.81%
196,536 $2.93 Million
Q3 2023

Nov 13, 2023

SELL
$4.19 - $7.35 $15,125 - $26,533
-3,610 Reduced 1.42%
251,360 $1.21 Million
Q2 2023

Aug 14, 2023

SELL
$4.37 - $9.56 $1.12 Million - $2.44 Million
-255,696 Reduced 50.07%
254,970 $1.91 Million
Q1 2023

May 08, 2023

BUY
$4.52 - $11.71 $210,799 - $546,119
46,637 Added 10.05%
510,666 $2.31 Million
Q4 2022

Feb 13, 2023

SELL
$9.51 - $12.95 $6,514 - $8,870
-685 Reduced 0.15%
464,029 $5.23 Million
Q3 2022

Nov 14, 2022

BUY
$8.23 - $15.14 $65,519 - $120,529
7,961 Added 1.74%
464,714 $4.45 Million
Q2 2022

Aug 15, 2022

BUY
$5.89 - $19.46 $2.37 Million - $7.84 Million
402,646 Added 744.17%
456,753 $3.7 Million
Q1 2022

May 13, 2022

BUY
$13.65 - $22.06 $738,560 - $1.19 Million
54,107 New
54,107 $914,000
Q4 2020

Feb 12, 2021

SELL
$34.11 - $112.26 $170,550 - $561,300
-5,000 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$29.36 - $47.1 $146,800 - $235,500
5,000 New
5,000 $188,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $76.2M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.